Disclosures: Thomas J. Schnitzer, MD, PhD: AstraZeneca (Products/Services: No) (Consultant/Advisory Board)Galapagos (Products/Services: No) (Consultant/Advisory Board)GlaxoSmithKlilne (Products/Services: No) (Consultant/Advisory Board)Lilly (Products/Services: No) (Consultant/Advisory Board, Research Grant or Support)PFizer (Products/Services: No) (Consultant/Advisory Board, Research Grant or Support)

Objective: To evaluate factors associated with satisfaction with medications for osteoarthritis (OA).

Design: Cross-sectional survey.Setting : United States primary and specialty outpatient care.Participants : Physicians (primary care physicians, rheumatologists, orthopedic surgeons), and their patients prescribed OA medication.

Interventions: Not applicable.

Main Outcome Measures: Patient-reported and physician-rated overall satisfaction with medications was assessed on a 5-point Likert scale (1, very satisfied; 5, very dissatisfied), in response to, ‘Which of the following options best describes your overall satisfaction with the prescribed medicine(s) for your osteoarthritis?’ (patients) and, ‘Which of the following statements best describes your satisfaction with the patient’s prescribed therapy (to treat their OA pain)?’ (physicians). Factors assessed for association with satisfaction included demographic, clinical and treatment characteristics. Covariates included in multiple linear regression included race and gender plus all significant covariates (two-tailed p < 0.25) in bivariate comparisons with outcome, the final set of factors identified using LASSO (least absolute shrinkage and selection operator).

Results: Responses from 153 physicians (81 in primary care, 35 rheumatologists, 37 orthopedic surgeons) and 572 patients (mean age 64.9 years) were analyzed. For patients, level of overall satisfaction was most strongly associated with lack of efficacy, rapid OA deterioration, and comorbid musculoskeletal pain; for physicians, lack of efficacy, treatment-resistant OA pain, and report that the best control had been achieved mattered most. Additional factors important only for patients included exercise and issues with drug interactions/comorbidities; whereas those only for physicians included issues with adverse events/tolerability, unemployment, most troublesome joint being a knee, lines of OA medications, obesity, and female gender.Conclusions: Satisfaction with prescribed medication for both patients and physicians across all specialties was most strongly associated with pain control. Additional important factors for patients were their physical activity and for physicians adverse events from medication. Funded by Pfizer and Lilly.

Level of Evidence: Level IV

« Back to AAPM&R Annual Assembly 2021

PM&R Meeting Abstracts - https://pmrjabstracts.org/abstract/treatment-satisfaction-with-medications-prescribed-for-osteoarthritis-cross-sectional-surveys-with-patients-and-physicians-in-the-united-states/